focus -WSS

focus

author：comprehensive 2025-08-12 08:29:18 - browse：262

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： How many hemophilia patients actually want gene therapy?

hotspot

WSS

FDA advisers back CAR

MoonLake credibility takes another hit with mid

White House calls on federal agencies to crack down on AI abuses

MoonLake credibility takes another hit with mid

Removing probiotics from the NICU could threaten preemies' health

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

hotspot

focus

focus

Duchenne breakthrough therapy leaves behind pioneering families

How many hemophilia patients actually want gene therapy?

Continuity nursing helped my family in our darkest PICU moments

Sanofi CEO defends move to abandon profit guidance, boost research

23andMe had bad news about my health. I wish a person had delivered it

First U.S. drug developed to treat liver disease MASH is approved

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

After affirmative action ruling, medical educators look to 'holistic review'

Extreme heat events are a public health emergency

Wikipedia

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

WuXi out of biotech trade group, U.S. and China relations to blame

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Male and female sex labels in research insufficient, scientists say

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Will General Catalyst be the first of many hospital takeovers?

focus

hotspot

Wikipedia

focus